Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics (NASDAQ: ELTX) reported its 2024 financial results and provided corporate updates. The company completed enrollment of 144 patients in its Phase 2 AMPLIFY-7P randomized study, with disease-free survival interim analysis expected in Q3 2025. Key financial results include:
- R&D expenses increased to $33.7M (vs $23.8M in 2023)
- G&A expenses decreased to $11.3M (vs $11.9M in 2023)
- Net loss widened to $51.9M (vs $35.2M in 2023)
- Cash position of $17.6M as of December 31, 2024
The company strengthened its position with a $10M registered direct offering in January 2025, extending operations into Q4 2025. Elicio aligned with FDA on key elements of planned ELI-002 Phase 3 study design and presented encouraging Phase 1a data showing 16.3-month median recurrence-free survival and 28.9-month median overall survival.
Elicio Therapeutics (NASDAQ: ELTX) ha riportato i risultati finanziari per il 2024 e fornito aggiornamenti aziendali. L'azienda ha completato l'arruolamento di 144 pazienti nel suo studio randomizzato di Fase 2 AMPLIFY-7P, con un'analisi intermedia sulla sopravvivenza libera da malattia prevista per il terzo trimestre del 2025. Risultati finanziari chiave includono:
- Le spese per R&S sono aumentate a $33,7M (rispetto a $23,8M nel 2023)
- Le spese generali e amministrative sono diminuite a $11,3M (rispetto a $11,9M nel 2023)
- La perdita netta è aumentata a $51,9M (rispetto a $35,2M nel 2023)
- Posizione di cassa di $17,6M al 31 dicembre 2024
L'azienda ha rafforzato la propria posizione con un'offerta diretta registrata di $10M a gennaio 2025, estendendo le operazioni nel quarto trimestre del 2025. Elicio si è allineata con la FDA su elementi chiave del design dello studio di Fase 3 ELI-002 e ha presentato dati incoraggianti della Fase 1a che mostrano una sopravvivenza mediane senza recidiva di 16,3 mesi e una sopravvivenza mediane globale di 28,9 mesi.
Elicio Therapeutics (NASDAQ: ELTX) reportó sus resultados financieros de 2024 y proporcionó actualizaciones corporativas. La compañía completó la inscripción de 144 pacientes en su estudio aleatorizado de Fase 2 AMPLIFY-7P, con un análisis intermedio de supervivencia libre de enfermedad esperado para el tercer trimestre de 2025. Resultados financieros clave incluyen:
- Los gastos de I+D aumentaron a $33.7M (en comparación con $23.8M en 2023)
- Los gastos generales y administrativos disminuyeron a $11.3M (en comparación con $11.9M en 2023)
- La pérdida neta se amplió a $51.9M (en comparación con $35.2M en 2023)
- Posición de efectivo de $17.6M al 31 de diciembre de 2024
La compañía fortaleció su posición con una oferta directa registrada de $10M en enero de 2025, extendiendo sus operaciones hasta el cuarto trimestre de 2025. Elicio se alineó con la FDA en elementos clave del diseño del estudio de Fase 3 ELI-002 y presentó datos alentadores de la Fase 1a que muestran una supervivencia libre de recurrencia mediana de 16.3 meses y una supervivencia global mediana de 28.9 meses.
Elicio Therapeutics (NASDAQ: ELTX)는 2024년 재무 결과를 보고하고 기업 업데이트를 제공했습니다. 이 회사는 144명의 환자를 대상으로 한 2상 AMPLIFY-7P 무작위 연구의 등록을 완료했으며, 질병 없는 생존에 대한 중간 분석은 2025년 3분기에 예상됩니다. 주요 재무 결과는 다음과 같습니다:
- 연구 및 개발 비용이 $33.7M로 증가했습니다 (2023년 $23.8M 대비)
- 일반 관리 비용이 $11.3M로 감소했습니다 (2023년 $11.9M 대비)
- 순손실이 $51.9M로 확대되었습니다 (2023년 $35.2M 대비)
- 2024년 12월 31일 기준 현금 보유액은 $17.6M입니다.
회사는 2025년 1월에 $10M의 등록된 직접 발행을 통해 입지를 강화했으며, 2025년 4분기까지 운영을 연장했습니다. Elicio는 ELI-002 3상 연구 설계의 주요 요소에 대해 FDA와 조율하였으며, 16.3개월의 중앙 재발 없는 생존 기간과 28.9개월의 중앙 전체 생존 기간을 보여주는 고무적인 1a상 데이터를 발표했습니다.
Elicio Therapeutics (NASDAQ: ELTX) a publié ses résultats financiers pour 2024 et a fourni des mises à jour sur l'entreprise. La société a terminé l'inscription de 144 patients dans son étude randomisée de Phase 2 AMPLIFY-7P, avec une analyse intermédiaire de la survie sans maladie prévue pour le troisième trimestre 2025. Les résultats financiers clés incluent :
- Les dépenses de R&D ont augmenté à 33,7 millions de dollars (contre 23,8 millions de dollars en 2023)
- Les dépenses générales et administratives ont diminué à 11,3 millions de dollars (contre 11,9 millions de dollars en 2023)
- La perte nette s'est élargie à 51,9 millions de dollars (contre 35,2 millions de dollars en 2023)
- Position de trésorerie de 17,6 millions de dollars au 31 décembre 2024
La société a renforcé sa position avec une offre directe enregistrée de 10 millions de dollars en janvier 2025, prolongeant ses opérations jusqu'au quatrième trimestre 2025. Elicio s'est alignée avec la FDA sur des éléments clés de la conception de l'étude de Phase 3 ELI-002 et a présenté des données encourageantes de la Phase 1a montrant une survie médiane sans récidive de 16,3 mois et une survie médiane globale de 28,9 mois.
Elicio Therapeutics (NASDAQ: ELTX) hat seine finanziellen Ergebnisse für 2024 veröffentlicht und Unternehmensaktualisierungen bereitgestellt. Das Unternehmen hat die Einschreibung von 144 Patienten in seine randomisierte Phase-2-Studie AMPLIFY-7P abgeschlossen, mit einer interimistischen Analyse zur krankheitsfreien Überlebensrate, die für das dritte Quartal 2025 erwartet wird. Wichtige finanzielle Ergebnisse umfassen:
- Die F&E-Ausgaben stiegen auf $33,7M (im Vergleich zu $23,8M im Jahr 2023)
- Die allgemeinen Verwaltungskosten sanken auf $11,3M (im Vergleich zu $11,9M im Jahr 2023)
- Der Nettoverlust weitete sich auf $51,9M aus (im Vergleich zu $35,2M im Jahr 2023)
- Die Liquiditätsposition betrug am 31. Dezember 2024 $17,6M.
Das Unternehmen stärkte seine Position mit einem registrierten Direktangebot von $10M im Januar 2025 und erweiterte die Aktivitäten bis ins vierte Quartal 2025. Elicio hat sich mit der FDA über wichtige Elemente des geplanten Studiendesigns der Phase 3 ELI-002 abgestimmt und ermutigende Daten aus der Phase 1a präsentiert, die eine mediane rezidivfreie Überlebenszeit von 16,3 Monaten und eine mediane Gesamtüberlebenszeit von 28,9 Monaten zeigen.
- Completed enrollment of Phase 2 AMPLIFY-7P trial with 144 patients
- FDA alignment achieved on Phase 3 study design elements
- Encouraging Phase 1a data with 16.3-month mRFS and 28.9-month mOS
- Strengthened cash position with $10M offering in January 2025
- Operations funded through Q4 2025
- Net loss increased to $51.9M from $35.2M in 2023
- R&D expenses increased 42% to $33.7M
- Required additional funding through registered direct offering
Insights
Elicio Therapeutics has reached a significant milestone with the completion of enrollment in their Phase 2 AMPLIFY-7P randomized trial for ELI-002, positioning them for a disease-free survival interim analysis in Q3 2025. This represents meaningful progress in their clinical development strategy for KRAS-mutant cancers, particularly pancreatic ductal adenocarcinoma (PDAC).
The FDA alignment on key elements of the planned Phase 3 study design is particularly noteworthy, as it reduces regulatory uncertainty and provides a clearer path to potential approval. Previously presented Phase 1a data demonstrated encouraging clinical signals, including a 16.3-month median recurrence-free survival and 28.9-month median overall survival, with strong correlation between T cell response strength and clinical outcomes.
The company's Amphiphile technology platform shows promise in enhancing cancer-specific T cell activation compared to conventional approaches. Their focus on KRAS mutations—which drive approximately 25% of all solid tumors—addresses a significant unmet medical need with substantial market potential. The observed antigen spreading beyond KRAS to patient-specific neoantigens suggests potential for broader immunological benefit.
While clinical development is proceeding according to plan, ELI-002 remains years from potential commercialization, with significant clinical hurdles yet to overcome in this highly challenging therapeutic area.
Elicio's financial position shows mixed signals with net losses increasing to
The company has taken steps to extend its cash runway with a
On a per-share basis, Elicio's net loss improved to
The modest improvement in G&A expenses (
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis
Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2024 and provided recent corporate and clinical updates.
“We made substantial progress in 2024 advancing our cancer immunotherapy pipeline and achieving major milestones, including completing enrollment in our first randomized Phase 2 clinical trial. We believe that ELI-002 could play a transformational role in preventing the recurrence of difficult-to-treat KRAS-mutant cancers,” said Robert Connelly, Chief Executive Officer of Elicio. “During the fourth quarter, we presented highly encouraging ELI-002 Phase 1a data at major medical meetings. Across two monotherapy trials that enrolled a total of 39 patients, we observed strong concordance between T cell response and anti-tumor activity—with antigen spreading beyond KRAS to other personalized tumor neo-antigens. Data presented at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting and the European Society for Medical Oncology (“ESMO”)Immuno-Oncology Congress 2024 pointed to a potential DFS benefit for patients. Reflecting strong interest from patients and trial investigators, enrollment in our Phase 2 AMPLIFY-7P trial was completed on schedule, and the study is progressing toward a DFS event-driven interim analysis expected in Q3 2025, depending on rate of event accrual. We’re looking forward to working with our investigators to initiate a clinical study of ELI-002 in additional KRAS-mutated tumor indications. Additionally, we have taken steps to strengthen our balance sheet to support operations into Q4 2025, beyond the upcoming interim analysis.”
Recent Highlights
- In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer.
- In January 2025, Elicio strengthened its cash position with a
$10.0 million registered direct offering of common stock. - In January 2025, Elicio reached alignment with regulatory authorities on a registrational strategy for ELI-002 in post-resection (adjuvant setting) mKRAS pancreatic ductal adenocarcinoma (“PDAC”). Specifically, Elicio aligned with the FDA on key elements of a planned Phase 3 study design—including dose, schedule, patient population and primary endpoint analysis based on DFS.
- In December 2024, Elicio announced the completion of enrollment of the randomized Phase 2 AMPLIFY-7P clinical trial (NCT05726864). The trial has successfully enrolled 144 post-resection mKRAS PDAC patients, randomized 2:1 to receive ELI-002 or observational standard-of-care.
- In December 2024, Elicio presented updated results from the Phase 1a AMPLIFY-201 clinical trial (NCT04853017) of ELI-002 at the ESMO Immuno-Oncology Congress 2024. Updated Phase 1a results included a 16.3-month median recurrence-free survival (“mRFS”), a 28.9-month median overall survival (“mOS”) from full study population and a strong correlation between mRFS and strength of T cell response.
- In November 2024, Elicio presented updated translational data from the Phase 1a AMPLIFY-7P clinical trial (NCT05726864) at the SITC 2024 Annual Meeting, demonstrating favorable safety, durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens and a strong correlation between DFS and T cell response.
Upcoming Anticipated Milestones
- DFS event-driven interim analysis of Phase 2 AMPLIFY-7P clinical trial in Q3 2025, depending on rate of event accrual
- Potential to finalize pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025
2024 Financial Results
R&D expense for 2024 was
G&A expense for 2024 was
Net loss for 2024 was
Cash and cash equivalents, as of December 31, 2024, were
Including
| ELICIO THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| (unaudited) | ||||||||
| Year Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 33,656 | $ | 23,849 | ||||
| General and administrative | 11,330 | 11,896 | ||||||
| Total operating expenses | 44,986 | 35,745 | ||||||
| Loss from operations | (44,986 | ) | (35,745 | ) | ||||
| Total other (expense) income, net | (6,912 | ) | 550 | |||||
| Net loss | (51,898 | ) | (35,195 | ) | ||||
| Other comprehensive gain (loss): | ||||||||
| Foreign currency translation adjustment | 22 | (197 | ) | |||||
| Comprehensive loss | $ | (51,876 | ) | $ | (35,392 | ) | ||
| Net loss per common share, basic and diluted | $ | (4.25 | ) | $ | (6.96 | ) | ||
| Weighted average common shares and pre-funded warrants outstanding, basic and diluted | 12,202,996 | 5,056,225 | ||||||
| ELICIO THERAPEUTICS, INC. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
| December 31, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 17,618 | $ | 12,894 | |||
| Other current assets | 3,075 | 3,454 | |||||
| Total current assets | 20,693 | 16,348 | |||||
| Other assets | 7,485 | 10,798 | |||||
| Total assets | $ | 28,178 | $ | 27,146 | |||
| Liabilities and stockholders' (deficit) equity | |||||||
| Current liabilities | $ | 11,523 | $ | 9,755 | |||
| Long-term liabilities | 27,967 | 6,018 | |||||
| Total liabilities | 39,490 | 15,773 | |||||
| Total stockholders' (deficit) equity | (11,312 | ) | 11,373 | ||||
| Total liabilities and stockholders' (deficit) equity | $ | 28,178 | $ | 27,146 | |||
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately
About ELI-002
Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer vaccine that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration.
ELI-002 2P (2-peptide formulation) has been studied in the Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017). ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in
About the Amphiphile Platform
Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based on preclinical studies.
Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.
The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue. In preclinical models, Elicio observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding the sufficiency of Elicio’s existing cash and cash equivalents to support operations; expectations about Elicio’s financial and operating results; Elicio’s planned clinical programs, including planned clinical trials and the potential to finalize pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in the second half of 2025, the potential of Elicio’s product candidates, including the potential transformational role ELI-002 could play in preventing the recurrence of difficult-to-treat KRAS-mutant cancers and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s financial condition, including its anticipated cash runway and ability to obtain the funding necessary to advance the development of ELI-002 and any other future product candidates, and Elicio’s ability to continue as a going concern; Elicio’s plans to develop and commercialize its product candidates, including ELI-002; the timing of initiation of Elicio’s planned clinical trials, including working with investigators to initiate the ELI-002 clinical study in additional KRAS-mutated tumor indications; the timing of the availability of data from Elicio’s clinical trials, including the DFS event-driven interim analysis, from the AMPLIFY-7P trial expected in the third quarter of 2025, depending on rate of event accrual; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the Annual Report on Form 10-K filed with the SEC on March 31, 2025, under the heading “Risk Factors” and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.
Investor Relations Contact
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com
FAQ
What were Elicio Therapeutics (ELTX) key financial metrics for 2024?
When is ELTX expecting interim analysis results for the AMPLIFY-7P Phase 2 trial?
How many patients were enrolled in ELTX's Phase 2 AMPLIFY-7P clinical trial?
What were the survival metrics from ELTX's Phase 1a trial of ELI-002?
How long will ELTX's current cash position support operations?
